Xin Lang Cai Jing·2026-01-05 08:08Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of a 24-valent pneumococcal polysaccharide conjugate vaccine, indicating progress in vaccine development aimed at preventing infections caused by 24 serotypes of pneumococcus [1] Group 1 - The vaccine utilizes a covalent combination of polysaccharide antigens and protein carriers, employing dual carrier technology [1] - It is intended for administration to individuals aged 2 months (minimum 6 weeks) and older [1] - The development of the vaccine is characterized by significant challenges and lengthy timelines, requiring clinical trial applications, execution of clinical trials, and drug registration approval before market launch [1]